Research Perspectives:

PRMT5 prognostic value in cancer

Hanine Lattouf, Coralie Poulard and Muriel Le Romancer _

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:3151-3153. https://doi.org/10.18632/oncotarget.26883

Metrics: PDF 1848 views  |   Full Text 2982 views  |   ?  


Hanine Lattouf1,2,3,4, Coralie Poulard1,2,3 and Muriel Le Romancer1,2,3

1 INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France

2 CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France

3 Université Lyon 1, Lyon, France

4 Lebanese University, EDST (Molecular Tumor-genesis and Anticancer Pharmacology), Hadath, Lebanon

Correspondence to:

Muriel Le Romancer, email: [email protected]

Keywords: arginine methylation; PRMT5; breast cancer; biomarker

Received: January 22, 2019    Accepted: February 03, 2019    Published: May 07, 2019


Protein arginine methyltransferases (PRMTs) catalyze the methylation of arginine residues on both histones and non-histone proteins. PRMT5, a member of the PRMT family, is overexpressed in a wide variety of cancers and its activity is associated with cell transformation. Moreover, its expression is associated with a decrease in patient survival in several cancers, a rationale for developing highly potent inhibitors of its enzymatic activity. However, most studies do not take into account the subcellular localization of PRMT5, which can modify its properties. Indeed, our team recently showed that PRMT5 nuclear expression is associated with prolonged survival. These results corroborated findings in prostate cancer, in which the nuclear fraction of PRMT5 was responsible for inhibiting cell growth, while the cytoplasmic fraction promoted cell growth. In conclusion, this criterion should be evaluated prior to administering PRMT5 inhibitors, which may have adverse effects.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26883